Literature DB >> 35115177

Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.

Wayne G Brisbane1, Alan M Priester2, Jorge Ballon3, Lorna Kwan2, Merdie K Delfin2, Ely R Felker2, Anthony E Sisk2, Jim C Hu4, Leonard S Marks2.   

Abstract

BACKGROUND: Systematic prostate biopsies add to the cancer detection rate of targeted biopsies, but the explanation for that increased sensitivity is not yet clear.
OBJECTIVE: To determine and quantify the utility of perilesional biopsies in the detection of clinically significant prostate cancer (csPCa). DESIGN, SETTING, AND PARTICIPANTS: Participants were 2048 men with magnetic resonance imaging (MRI) lesions (grades 3-5) who underwent targeted and systematic prostate biopsy via MRI/ultrasound fusion at University of California Los Angeles and Cornell between 2011 and 2019. The study is a retrospective examination of prospectively acquired data. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All biopsy cores (30191), locations of which had been stored digitally in the image-fusion device, were analyzed for tissue pathology and relationship with MRI lesions. A validated Matlab script was used to determine the distance between MRI lesions and cores containing csPCa (3552 cores from 927 men). Significance of distance measurements was determined by multilevel, multivariable logistic regression to account for within patient-biopsy correlation and control for patient characteristics. RESULTS AND LIMITATIONS: Overall, 90% (95% confidence interval [CI] = 89-91) of csPCa cores (3206/3552) were located within a radius of 10 mm from the nearest lesion: 65% (95% CI = 63-67) within the region of interest (ROI) and 26% (95% CI = 24-27) outside the ROI but within the 10-mm "penumbra." The width of the penumbra or concentric band, which enclosed 90% of csPCa, was primarily related to MRI grade of lesion: grade 5, 5 mm; grade 4, 12 mm; grade 3, 16 mm. In 18% (95% CI = 15-20) of patients (166/927), csPCa was diagnosed only by sampling outside the MRI lesion, the yield decreasing with increasing distance. Limitations of MRI interpretation and fusion biopsy performance could affect the utility of these data in individual patients.
CONCLUSIONS: Perilesional biopsies, that is, samples taken from a band of 10-mm radius outside MRI lesions (the penumbra), contain most cores of csPCa that are not present within the lesion. These data may help increase the performance characteristics of targeted prostate biopsy. PATIENT
SUMMARY: We studied the locations of cancer within the prostate in men undergoing magnetic resonance imaging (MRI)-guided biopsy. We found that not all cancers are located within the MRI lesion, but 90% (95% confidence interval = 89-91) of the cancers arewithin 1 cm of the lesions. Biopsies taken from both within and around MRI lesions provide greater sensitivity for cancer detection than samples taken from the lesion only.
Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging; Prostate biopsy; Prostate cancer

Mesh:

Year:  2022        PMID: 35115177     DOI: 10.1016/j.eururo.2022.01.008

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   24.267


  3 in total

Review 1.  Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway.

Authors:  Tristan Barrett; Maarten de Rooij; Francesco Giganti; Clare Allen; Jelle O Barentsz; Anwar R Padhani
Journal:  Nat Rev Urol       Date:  2022-09-27       Impact factor: 16.430

2.  [Image-guided biopsy of the prostate gland].

Authors:  August Sigle; Jakob Michaelis; Dominik Schöb; Matthias Benndorf; Lars Schimmöller; Benedikt Becker; Maximilian Pallauf; Andreas J Gross; Thomas R W Herrmann; Jan-Thorsten Klein; Lukas Lusuardi; Christopher Netsch; Axel Häcker; Jens Westphal; Cordula Jilg; Christian Gratzke; Arkadiusz Miernik
Journal:  Urologie       Date:  2022-08-30

3.  Magnetic Resonance Imaging-targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer.

Authors:  Nicolette G Alkema; Sebastiaan F J S Hoogeveen; Evelyne C C Cauberg; Lambertus P W Witte; Miranda van 't Veer-Ten Kate; Erwin de Boer; Marije A M Hoogland; Marco H Blanker; Martijn F Boomsma; Martijn G Steffens
Journal:  Eur Urol Open Sci       Date:  2022-09-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.